ITRM20130657A1 - Trattamento delle dermatopatie mediante estratto vegetale di daphne laureola - Google Patents
Trattamento delle dermatopatie mediante estratto vegetale di daphne laureolaInfo
- Publication number
- ITRM20130657A1 ITRM20130657A1 IT000657A ITRM20130657A ITRM20130657A1 IT RM20130657 A1 ITRM20130657 A1 IT RM20130657A1 IT 000657 A IT000657 A IT 000657A IT RM20130657 A ITRM20130657 A IT RM20130657A IT RM20130657 A1 ITRM20130657 A1 IT RM20130657A1
- Authority
- IT
- Italy
- Prior art keywords
- psoriasis
- phytocomplex
- extracts
- dermatitis
- treatment
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims description 46
- 241000271305 Daphne laureola Species 0.000 title claims description 44
- 238000011282 treatment Methods 0.000 title claims description 24
- 201000004681 Psoriasis Diseases 0.000 claims description 45
- 239000002537 cosmetic Substances 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 18
- 201000004624 Dermatitis Diseases 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- 230000000699 topical effect Effects 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 10
- 230000001684 chronic effect Effects 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- -1 for example Substances 0.000 claims description 8
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 5
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 239000003974 emollient agent Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 239000002453 shampoo Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 206010012442 Dermatitis contact Diseases 0.000 claims description 3
- 206010037575 Pustular psoriasis Diseases 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 208000010247 contact dermatitis Diseases 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 206010018797 guttate psoriasis Diseases 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 230000001256 tonic effect Effects 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 102000016942 Elastin Human genes 0.000 claims description 2
- 108010014258 Elastin Proteins 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 239000004904 UV filter Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000645 desinfectant Substances 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 229920002549 elastin Polymers 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 150000002334 glycols Chemical class 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000003605 opacifier Substances 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 3
- 239000010425 asbestos Substances 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 37
- 210000003491 skin Anatomy 0.000 description 17
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000002510 keratinocyte Anatomy 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- 229940100601 interleukin-6 Drugs 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 241001310717 Daphne genkwa Species 0.000 description 7
- 230000002682 anti-psoriatic effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 206010040844 Skin exfoliation Diseases 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000001185 psoriatic effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 229940047122 interleukins Drugs 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 241000934856 Daphne Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010048649 Koebner phenomenon Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 238000009193 PUVA therapy Methods 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 208000005775 Parakeratosis Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 206010061372 Streptococcal infection Diseases 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229960005339 acitretin Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 230000003822 cell turnover Effects 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 2
- 229960002199 etretinate Drugs 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 239000003410 keratolytic agent Substances 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 239000009027 Danshen-Gegen Substances 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 240000000279 Emilia sonchifolia Species 0.000 description 1
- 235000002139 Emilia sonchifolia Nutrition 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000097097 Laurella Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 244000172730 Rubus fruticosus Species 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 241001534930 Thymelaeaceae Species 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000010975 amethyst Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- NFDRPXJGHKJRLJ-UHFFFAOYSA-N edtmp Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CCN(CP(O)(O)=O)CP(O)(O)=O NFDRPXJGHKJRLJ-UHFFFAOYSA-N 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000657A ITRM20130657A1 (it) | 2013-11-27 | 2013-11-27 | Trattamento delle dermatopatie mediante estratto vegetale di daphne laureola |
| PCT/IT2014/000312 WO2015079469A1 (en) | 2013-11-27 | 2014-11-26 | Daphne laureola extracts in the treatment of dermopathies |
| CA2930821A CA2930821C (en) | 2013-11-27 | 2014-11-26 | Daphne laureola extracts in the treatment of dermopathies |
| EP14838804.4A EP3082836B1 (en) | 2013-11-27 | 2014-11-26 | Daphne laureola extract and its use for the treatment of dermopathies |
| US15/100,104 US10098923B2 (en) | 2013-11-27 | 2014-11-26 | Daphne laureola extracts in the treatment of dermopathies |
| JP2016535157A JP6556720B2 (ja) | 2013-11-27 | 2014-11-26 | 皮膚症の治療におけるダフネ・ラウレオラ抽出物 |
| ES14838804T ES2856498T3 (es) | 2013-11-27 | 2014-11-26 | Extracto de Daphne laureola y su uso para el tratamiento de dermopatías |
| US16/160,847 US10588931B2 (en) | 2013-11-27 | 2018-10-15 | Daphne laureola extracts in the treatment of dermopathies |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000657A ITRM20130657A1 (it) | 2013-11-27 | 2013-11-27 | Trattamento delle dermatopatie mediante estratto vegetale di daphne laureola |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITRM20130657A1 true ITRM20130657A1 (it) | 2015-05-28 |
Family
ID=49841755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT000657A ITRM20130657A1 (it) | 2013-11-27 | 2013-11-27 | Trattamento delle dermatopatie mediante estratto vegetale di daphne laureola |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10098923B2 (https=) |
| EP (1) | EP3082836B1 (https=) |
| JP (1) | JP6556720B2 (https=) |
| CA (1) | CA2930821C (https=) |
| ES (1) | ES2856498T3 (https=) |
| IT (1) | ITRM20130657A1 (https=) |
| WO (1) | WO2015079469A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109350673B (zh) * | 2018-10-17 | 2021-07-02 | 吕梁学院 | 用于治疗银屑病的中药组合物、药膏及其制备方法 |
| EP3666250A1 (en) | 2018-12-10 | 2020-06-17 | ETH Zurich | Cosmetic preparations comprising daphne extracts |
| US10713455B1 (en) | 2019-03-27 | 2020-07-14 | Toshiba Global Commerce Solutions | Point-of-sale terminal with mirrors arranged around scan zone |
| CN115337392B (zh) * | 2022-08-09 | 2023-07-21 | 海孵(海南自贸区)医疗科技有限责任公司 | 一种重组iii型人源化胶原蛋白凝胶及其制备方法、应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB479688A (en) * | 1936-08-07 | 1938-02-07 | Louisa Caroline Humphreys | Improvements relating to veterinary medicines |
| US20120039928A1 (en) * | 2008-05-02 | 2012-02-16 | Jun Seong Park | Medicinal plants extract using processing of herbal medicine and composition of skin external application comprising the same |
| WO2012157978A2 (ko) * | 2011-05-17 | 2012-11-22 | 한국생명공학연구원 | 팥꽃나무 추출물, 이의 분획물 또는 이로부터 분리한 화합물을 유효성분으로 함유하는 아토피 예방 또는 치료용 약학적 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000053557A (ja) * | 1998-08-11 | 2000-02-22 | Ichimaru Pharcos Co Ltd | 保湿性植物抽出物を含有する化粧料組成物 |
| US20050003023A1 (en) * | 2002-06-28 | 2005-01-06 | Meisner Lorraine Faxon | Topical composition for the treatment of psoriasis and related skin disorders |
| KR100839030B1 (ko) * | 2006-12-19 | 2008-06-19 | 담양군 | 아토피 피부염 개선용 조성물과 여드름 개선용 조성물 |
| CN101181427B (zh) * | 2007-11-21 | 2010-11-10 | 布焕景 | 治疗牛皮癣的外用药物 |
| KR100946562B1 (ko) * | 2008-01-31 | 2010-03-11 | 이화여자대학교 산학협력단 | 원화 추출물로부터 분리된 화합물을 유효성분으로 함유하는암 질환의 예방 및 치료용 조성물 |
-
2013
- 2013-11-27 IT IT000657A patent/ITRM20130657A1/it unknown
-
2014
- 2014-11-26 CA CA2930821A patent/CA2930821C/en active Active
- 2014-11-26 ES ES14838804T patent/ES2856498T3/es active Active
- 2014-11-26 EP EP14838804.4A patent/EP3082836B1/en active Active
- 2014-11-26 JP JP2016535157A patent/JP6556720B2/ja active Active
- 2014-11-26 US US15/100,104 patent/US10098923B2/en active Active
- 2014-11-26 WO PCT/IT2014/000312 patent/WO2015079469A1/en not_active Ceased
-
2018
- 2018-10-15 US US16/160,847 patent/US10588931B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB479688A (en) * | 1936-08-07 | 1938-02-07 | Louisa Caroline Humphreys | Improvements relating to veterinary medicines |
| US20120039928A1 (en) * | 2008-05-02 | 2012-02-16 | Jun Seong Park | Medicinal plants extract using processing of herbal medicine and composition of skin external application comprising the same |
| WO2012157978A2 (ko) * | 2011-05-17 | 2012-11-22 | 한국생명공학연구원 | 팥꽃나무 추출물, 이의 분획물 또는 이로부터 분리한 화합물을 유효성분으로 함유하는 아토피 예방 또는 치료용 약학적 조성물 |
Non-Patent Citations (3)
| Title |
|---|
| A. PIERONI ET AL: "Natural Remedies and Nutraceuticals Used in Ethnoveterinary Practices in Inland Southern Italy", VETERINARY RESEARCH COMMUNICATIONS, vol. 28, no. 1, 1 January 2004 (2004-01-01), pages 55 - 80, XP055105721, ISSN: 0165-7380, DOI: 10.1023/B:VERC.0000009535.96676.eb * |
| DATABASE WPI Week 201279, Derwent World Patents Index; AN 2012-Q30314, XP002721193 * |
| DISCORIDES PEDANIUS: "Thymelaea (Spurge-laurel)", 2012, XP002721191, Retrieved from the Internet <URL:http://art.thewalters.org/detail/6758/thymelaea-spurge-laurel/> [retrieved on 20120305] * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2930821C (en) | 2023-10-17 |
| EP3082836A1 (en) | 2016-10-26 |
| ES2856498T3 (es) | 2021-09-27 |
| CA2930821A1 (en) | 2015-06-04 |
| US10098923B2 (en) | 2018-10-16 |
| WO2015079469A1 (en) | 2015-06-04 |
| EP3082836B1 (en) | 2020-12-02 |
| JP6556720B2 (ja) | 2019-08-07 |
| WO2015079469A8 (en) | 2016-05-06 |
| US20190151395A1 (en) | 2019-05-23 |
| JP2017501982A (ja) | 2017-01-19 |
| US20170000838A1 (en) | 2017-01-05 |
| US10588931B2 (en) | 2020-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102257524B1 (ko) | 피부 진정 및 재생효과를 지니는 병풀 유래 엑소좀 함유 피부 개선용 화장료 조성물 | |
| KR102309958B1 (ko) | 구근추출물을 포함하는 피부 개선용 조성물 | |
| JPWO2004016236A1 (ja) | 化粧料 | |
| KR20110131498A (ko) | 패각 또는 패산호로부터 추출한 알카리용액에 은이온을 포함하는 항균제와 이를 포함하여 조성된 조성물. | |
| KR20230166109A (ko) | 식물 유래 엑소좀-유사 나노소포 또는 엑소좀을 포함하는 조성물 및 그의 사용 방법 | |
| JP5990058B2 (ja) | エストロゲン受容体β活性化剤 | |
| KR20110082292A (ko) | 아토피 및 여드름 피부에 효능을 보이는 황칠나무 추출물 | |
| US10588931B2 (en) | Daphne laureola extracts in the treatment of dermopathies | |
| KR102358611B1 (ko) | 호장근 뿌리 추출물을 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물 | |
| RU2541804C2 (ru) | Лечение и/или предотвращение воспаления и фотоповреждения кожи и фотозащита кожи с помощью водорастворимого экстракта растения рода solanum | |
| KR20160008055A (ko) | 동백잎 추출물을 유효성분으로 포함하는 체모 또는 피부 상태 개선용 조성물 | |
| KR100702327B1 (ko) | 자극완화 효과를 갖는 동백꽃 추출물을 함유하는 화장료조성물 | |
| KR101484033B1 (ko) | 땅콩 껍질 추출물을 포함하는 탈모방지 또는 발모촉진용 조성물 | |
| KR20140091376A (ko) | 국화 추출물을 포함하는 탈모방지 또는 발모촉진용 조성물 | |
| JP2010024211A (ja) | 細胞増殖促進剤 | |
| JP4197194B2 (ja) | 細胞間接着抑制用経口投与剤 | |
| KR20110108481A (ko) | 인삼 사포닌 대사체를 포함하는 탈모방지 또는 발모촉진용 조성물 | |
| KR20170010499A (ko) | 달팽이 점액 발효여과물을 유효성분으로 하는 피부장벽 개선 및 높은 피부 흡수율을 갖는 화장료 조성물과 기능성 화장품 | |
| KR102297607B1 (ko) | 며느리배꼽을 포함하는 아토피 피부 개선 및 피부 보습용 조성물 | |
| KR102093708B1 (ko) | 침피 추출물을 이용한 화장료 조성물 | |
| KR101438332B1 (ko) | 포시티아사이드-에이를 포함하는 탈모방지 또는 발모촉진용 조성물 | |
| CN117412755A (zh) | 包含植物来源的外泌体样纳米囊泡或外泌体的组合物及其使用方法 | |
| KR102034436B1 (ko) | 베트남 후피향 추출물을 포함하는 아토피 피부염 치료 및 예방용 조성물 | |
| KR20220114212A (ko) | 하늘타리 추출물을 유효성분으로 포함하는 피부 재생 또는 상처 치료용 조성물 | |
| JP6002510B2 (ja) | エストロゲン受容体β活性化剤 |